scholarly journals Patients’ oncological therapy depends on their pre-treatment quality of life

2021 ◽  
Vol 48 ◽  
pp. 102043
Author(s):  
Anja Thronicke ◽  
Shiao Li Oei ◽  
Friedemann Schad
Keyword(s):  
Quality Of Life ◽  
Treatment Quality ◽  
Oncological Therapy ◽  
Pre Treatment

The Effect of Treatment on Quality of Life, Symptoms, and Social Life in Gynecologic Cancer Patients

2021 ◽  
pp. 105477382110523
Author(s):  
Serap Tekbaş ◽  
Nevin Hotun Şahin ◽  
Niyazi Cenk Sayın
Keyword(s):  
Quality Of Life ◽  
Social Life ◽  
Gynecologic Cancer ◽  
Treatment Quality ◽  
Social Activities ◽  
Cancer Data ◽  
Edmonton Symptom Assessment Scale ◽  
Effect Of Treatment ◽  
Pre Treatment

This study was carried out to determine the effect of treatment on quality of life, symptoms, and social life in patients with gynecologic cancer. Data were collected through face-to-face interviews to evaluate the individual and disease characteristics of the patients. The Edmonton Symptom Assessment Scale was used to determine the severity of the side effects. Functional Assessment of Cancer Therapy-General 4 was used to evaluate the quality of life. The total post-treatment quality of life scores of the patients were lower than their total pre-treatment scores. Patients who received chemotherapy and chemoradiotherapy had a lower quality of life than those who received radiotherapy, and they were less involved in social activities. Half of the individuals participated in social activities in the pre-treatment period, but this rate decreased to 16.4% after the treatment started. In this study, the quality-of-life scores of the patients who received gynecologic cancer treatment decreased after treatment and the patients experienced many symptoms at an increasingly severe level.

scholarly journals The role of trans obturator tape as a surgical procedure for female stress urinary incontinence and its impact on quality of life in Jammu region

2019 ◽  
Vol 8 (12) ◽  
pp. 4975
Author(s):  
Sapna Puri ◽  
Manisha Kohli
Keyword(s):  
Quality Of Life ◽  
Stress Incontinence ◽  
Symptomatic Relief ◽  
Female Stress Urinary Incontinence ◽  
Medical Sciences ◽  
King’S Health Questionnaire ◽  
Promising Treatment ◽  
Pre Treatment

Background: Stress incontinence is one of the most common but debilitating health issue among women. It has a detrimental effect on overall health and quality of life of women. Trans obturator tape (TOT) has emerged as a promising treatment modality. The aim of present study was to assess the usefulness of TOT in terms of change in quality of life of stress incontinence patients.Methods: The study was performed at Department of Obstetrics and Gynecology, Acharya Shri Chandler of Medical Sciences (ASCOMS), Jammu. A total of 50 symptomatic women were enrolled in the study and underwent TOT procedure using outside-in technique. The quality of life of women was assessed at enrolment and 12 months after the procedure using King’s Health Questionnaire (KHQ). Change in QOL was assessed using paired ‘t’-test.Results: After 12 months follow-up, a total of 27 (54%) patients were entirely symptom free. As compared to pre-treatment QOL assessment on KHQ for general health/incontinence impact, quality of life and symptom scores a % decline of 73.2%, 79.8% and 78.4% was observed. For all the three parts, the change in scores was significant statistically. No other complications and side effects were reported.Conclusions: TOT is a useful procedure which provided symptomatic relief as well as QOL enhancement.

scholarly journals Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer

2017 ◽  
Vol 26 (6) ◽  
pp. 1635-1645 ◽  
Author(s):  
Lionne D. F. Venderbos ◽  
Shafak Aluwini ◽  
Monique J. Roobol ◽  
Leonard P. Bokhorst ◽  
Eric H. G. M. Oomens ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Treatment Quality ◽  
Life Outcomes ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer ◽  
Long Term Follow Up

scholarly journals Comparison of effects of medicinal cannabis or standard palliative care on quality of life of patients with cholangiocarcinoma in Northeast Thailand

F1000Research ◽  
2022 ◽  
Vol 11 ◽  
pp. 20
Author(s):  
Narisara Phansila ◽  
Chaiyasit Sittiwet ◽  
Ranee Wongkongdech
Keyword(s):  
Quality Of Life ◽  
Palliative Care ◽  
Rank Test ◽  
Northeast Thailand ◽  
Care Clinic ◽  
Early Access ◽  
Signed Rank Test ◽  
Medicinal Cannabis ◽  
Pre Treatment

Background: Cholangiocarcinoma (CCA) has a poor prognosis and is a major cause of mortality and suffering in Thailand’s Northeastern (Isaan) Region.   Methods: This prospective cohort study aimed to compare the health-related quality of life (HRQoL) among 72 newly diagnosed CCA patients; 42 patients who received cannabis treatment (CT) and 30 patients who received a standard palliative care treatment (ST). The study was carried out between 1st September 2019 to 31st October 2020.  Data were collected from patients from oncology clinics of six hospitals in five provinces of northeast Thailand. The HRQoL was measured at baseline, and at 2 and 4 months after diagnosis by the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaires QLQ-C30, and QLQ-BIL21. The Mann-Whitney U-test was performed to compare quality of life scores between the two patient groups and Wilcoxon signed rank test was performed to compare within groups QoL scores at pre-treatment, and 2 and 4 month follow-ups. Results: Global health status and functional scales, for both groups were high at pre-treatment. At 2 and 4 month follow-up, CT group patients had consistent statistically significantly better Palliative Performance Scale (PPS), and QoL scores, and many symptom scores than the ST group.   Conclusions: Medicinal cannabis may increase QoL for advanced CCA patients. Our findings support the importance of early access to palliative cannabis care clinic before the terminal and acceleration phase close to death.

scholarly journals Near vision correction and quality of life among textile factory workers in Durban

2017 ◽  
Vol 76 (1) ◽  
Author(s):  
Ving F. Chan ◽  
Jyoti Naidoo ◽  
Farai S. Chinanayi ◽  
Kovin S. Naidoo
Keyword(s):  
Quality Of Life ◽  
Vision Impairment ◽  
Factory Workers ◽  
Near Vision ◽  
Related Quality ◽  
Visual Function Questionnaire ◽  
Pre Treatment ◽  
Textile Factory ◽  
Textile Factory Workers

Background: Uncorrected near vision impairment affects the performance of near vision tasks and activities for an estimated 410 million people worldwide. Once normal vision becomes blurred or impaired, the ordinary and simple daily routines of individuals become difficult; often resulting in frustration and irritation, which is consequently reflected in their quality of life.Aim: We investigated the change of vision-related quality of life (VRQoL) following near correction among textile factory workers in South Africa.Methods: Presbyopic subjects who were 40 years and older with no other eye conditions were provided near spectacle correction. We interviewed subjects to ascertain their VRQoL scores using the National Eye Institute Visual Function Questionnaire, pre-treatment and 6 months after the provision of near corrections.Setting: The study was conducted among the textile factory workers in KwaZulu-Natal, South Africa.Results: A total of 423 textile factory workers were followed up from seven textile factories in Durban. The overall increase in VRQoL scores of 21.9 (95% CI 16.7–27) was significant (p < 0.01). This translates to a 36.5% (95% CI 30.6–42.4) change in VRQoL. The increase was highest among participants of African origin 25.1 (95% CI 21.14–29.1), males 18.8 (95% CI 12.6–27.2), among those who had completed primary school 35.8 (95% CI 21.7–49.9) and among participants with other responsibilities (ironing and quality assurance) 21.9 (95% CI 16.7–27).Conclusion: Correcting near vision impairment improved the VRQoL scores of textile factory workers. The results showed that VRQoL scores increased significantly across levels of education and categories of responsibility

Bipolar Disorders and Their Clinical Management, Part II: Diagnosis, Differential Diagnosis, and Treatment

2019 ◽  
Author(s):  
Bernadette DeMuri-Maletic ◽  
Vladimir Maletic
Keyword(s):  
Quality Of Life ◽  
Bipolar Disorder ◽  
Differential Diagnosis ◽  
Bipolar Disorders ◽  
Psychosocial Interventions ◽  
Diagnosis And Treatment ◽  
Treatment Quality ◽  
Treatment Modalities ◽  
The Impact

Bipolar disorder is a biologically and phenotypically diverse disorder and its diagnosis and treatment provides a significant challenge to even the most seasoned clinician. We provide an update on the diagnosis and differential diagnosis of bipolar disorder, reflecting recent changes in DSM-5. Our review provides a succinct summary of the treatment literature, encompassing pharmacologic and psychosocial interventions for bipolar depression, mania/hypomania, mixed states, and prevention of disease recurrence. We provide a brief critical review of emerging treatment modalities, including those used in treatment resistance. Challenges involved in maintaining adherence are further discussed. Additionally, we review common treatment adverse effects and provide recommendations for proper side effect monitoring. There is evidence of significant functional impairment in patients with bipolar disorder and we conclude with a discussion of the impact of impairment on prognosis and quality of life. This review contains 4 figures, 8 tables, and 45 references. Key Words: bipolar disorders, differential diagnosis, maintenance pharmacotherapy, prognosis, psychosocial interventions, treatment, quality of life

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

1998 ◽  
Vol 16 (7) ◽  
pp. 2382-2391 ◽  
Author(s):  
J H Fetting ◽  
R Gray ◽  
D L Fairclough ◽  
T J Smith ◽  
K A Margolin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Survival Rate ◽  
Dose Intensity ◽  
Treatment Quality ◽  
Cancer Outcomes ◽  
Node Positive ◽  
Tests Of Significance ◽  
Breast Cancer Outcomes

PURPOSE The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF). The 16-week regimen features greater doxorubicin and 5-FU dose-intensity than CAF and improved scheduling of antimetabolites with sequential methotrexate and 5-FU, as well as infusion 5-FU. PATIENTS AND METHODS A total of 646 node-positive, receptor-negative patients were randomly assigned to receive either the 1 6-week regimen or six cycles of CAF. Breast cancer outcomes included recurrence as well as disease-free and overall survival. Toxicity was evaluated by the Common Toxicity Criteria (CTC). Treatment-related quality of life was assessed by the Breast Chemotherapy Questionnaire (BCQ) before, during, and 4 months after treatment in 163 patients. The trial was designed to use one-sided tests of significance for power calculations, but is now reported with both one-sided and the traditional two-sided tests of significance. RESULTS At a median follow-up of 3.9 years, the estimated 4-year recurrence-free survival rate was 67.5% with the 16-week regimen versus 62.7% with CAF (P = .19, two-sided; P = .095, one-sided). The estimated 4-year survival rate was 78.1% with the 16-week regimen versus 71.4% with CAF (P = .10, two-sided; P = .05, one-sided). CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver and cardiac toxicity, whereas the 16-week regimen produced significantly higher grades of anemia, nausea, stomatitis, and weight loss, as well as skin and neurotoxicity. There were three treatment-related deaths with CAF but none with the 16-week regimen. During treatment, quality of life declined significantly more with the 16-week regimen than CAF, but by 4 months posttreatment, there was no difference. CONCLUSION The 16-week regimen produced marginally better breast cancer outcomes than CAF with similar toxicity but a greater reduction in during-treatment quality of life. The 16-week regimen should not be used instead of a standard-dose regimen without careful consideration of the 16-week regimen's pros and cons, which include its complicated schedule. It should probably not be tested further, but its antimetabolite schedules and frequent drug administration (ie, dose density) should be considered in the development of new regimens.

Sign in / Sign up

Export Citation Format

Share Document